Compare Extra Space Storage, Inc. (EXR) vs Neurocrine Biosciences Inc (NBIX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Extra Space Storage, Inc. vs Neurocrine Biosciences Inc — how do they compare? Extra Space Storage, Inc. trades at $133.26 (market cap $28.12B), while Neurocrine Biosciences Inc trades at $141.09 (market cap $14.36B). The key difference: Extra Space Storage, Inc. is the larger of the two by market cap, and Extra Space Storage, Inc. pays a 4.87% dividend while Neurocrine Biosciences Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Extra Space Storage, Inc. for 108 Days and Neurocrine Biosciences Inc for 23 Days on average.
| EXR | NBIX | |
|---|---|---|
Market Cap | $28.12B | $14.36B |
Volume | 2,595,579 | 1,237,180 |
Sector | Real Estate | Health |
52-Week High | $152.85 | $185.50 |
52-Week Low | $126.67 | $123.10 |
Typical Hold Time | 108 Days | 23 Days |
Enterprise Value | $41.84B | $14.37B |
Dividend Yield | 4.87% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Extra Space Storage (EXR) trades at $131.70, down 1.64% with a bearish technical signal. The company maintains strong fundamentals with consistent earnings beats, 27.79% net margin, and $974M net income. Revenue growth has been steady from $1.9B in 2022 to $3.4B in 2025. Analyst consensus is split with 14 Buy and 14 Hold ratings, targeting $158.33 average price. Recent leadership transition to Noah Springer as CEO effective January 2027 adds strategic focus.
EXR presents a balanced risk-reward profile with solid operational performance offset by technical weakness. The REIT's scale, 94.2% occupancy, and dividend yield support long-term value, though current price action suggests near-term pressure. Debt levels at 46.63% debt-to-asset ratio require monitoring amid rising interest rates. Upside potential exists if Q3 2026 earnings beat expectations on October 27.
Neurocrine Biosciences (NBIX) trades at $143.47, down 1.4% on the day, amid a bearish technical signal. The stock shows strong fundamentals with a 20.91% net income margin and consistent earnings beats, including a Q2 2026 EPS of $2.85 versus $1.85 expected. Recent news highlights pipeline advancements in Prader-Willi syndrome and active participation in investor conferences. Key support is at $142, with resistance at $145.
The outlook is positive, driven by robust product growth, particularly from Ingrezza and Crenessity, and a deep pipeline. Risks include pricing pressures on Ingrezza by 2029 and execution challenges in portfolio expansion. Analyst consensus is strongly bullish with a $204.18 price target, suggesting significant upside from current levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Extra Space Storage, Inc.
Extra Space Storage is a fully integrated real estate investment trust that owns, operates, and manages almost 2,100 self-storage properties in 41 states, with over 160 million net rentable square feet of storage space. Of these properties, approximately one half is wholly owned, while some facilities are owned through joint ventures and others are owned by third parties and managed by Extra Space Storage in exchange for a management fee.
Read more on EXR →About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →
